Recent studies show that patients with the most serious forms of the coronavirus had high levels of IL-6, a common inflammatory cytokine, which MediSieve has previously encountered while researching sepsis and cytokine storms.

Finding a way to selectively and rapidly target and remove IL-6 from COVID-19 patients’ bloodstream could be extremely beneficial.

Currently, the majority of severe COVID-19 patients are treated with immunoblockers or immunosuppressants. While still effective treatments, their most dangerous drawback is that the suppressants stay in the bloodstream, leaving patients immunsupressed while fighting the infection.

Broad risk groups

Immune deficient Inpatients

Pregnant

Over 70s

Significant worldwide burden

26m confirmed cases
850k deaths

High morbidity

Respiratory distress

Sepsis

Long patient care

Second wave threat

120k hospital deaths
estimated in the UK

By focusing specifically on IL-6 MediSieve can rapidly bring a product to market to alleviate the cytokine storm and hyperimmune reaction as well as the secondary sepsis that is the cause of significant mortality in COVID-19 patients. In vitro data suggest that adult IL-6 levels could be reduced by 80% in 4 hours.

Latest News

Job Posting: Regulatory Affairs Manager

Job Posting: Regulatory Affairs Manager
November 25, 2020

Job Title: Regulatory Affairs Manager Reports to : CTO  Start Date : ASAP  Hours of Work : Full-time Salary : £50-60k PA  Closing Date : December 2020 (or earlier if a suitable candidate is found)  Please send your  CV and a cover letter  explaining what you can...
Job Posting: Product Development Scientist

Job Posting: Product Development Scientist
November 12, 2020

Job Title: Product Development Scientist Reports to : CTO  Start Date : ASAP  Hours of Work : Full-time Salary : £37.5 - 45k PA  Closing Date : December 2020 (or earlier if a suitable candidate is found)  Please send your  CV and a cover letter  explaining what ...